维亚生物(01873)出售于一间投资孵化企业的股权

智通财经
Dec 14

智通财经APP讯,维亚生物(01873)发布公告,Arthrosi Therapeutics已知会本公司,于2025年12月13日,买方Sobi US Holding Corp.已同意透过并购方式收购Arthrosi Therapeutics。紧随完成后,本公司将不再持有Arthrosi Therapeutics的任何股权。并购协议当中规定于完成时支付的预付款为9.5亿美元(可作出惯常调整)及或然代价不超过5.5亿美元。

Arthrosi Therapeutics为一间特拉华州公司,其乃临床阶段的生物技术公司,聚焦pozdeutinurad的开发,其为潜在同类最优、高效且高选择性的新一代URAT1抑制剂,旨在降低进行性痛风患者的血清尿酸水平、减少急性发作及痛风石。截至本公告日期,维亚孵化器持有Arthrosi Therapeutics股本中约3.14%的股权(按悉数摊薄及转换后的基准计算)。

董事认为,并购能够令本集团变现其自投资以来长期累积的于Arthrosi Therapeutics的投资价值,且为当前加强本集团财务灵活性的机会。本集团拟将自并购收到的所得款项用于补充本集团的营运资金,并支持本集团其他投资及孵化业务的增长与发展。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10